Close menu

news|financial Logo
 

January 20th, 2022 | 11:08 CET

Cardiol, Novavax, Valneva - Why it's worth buying now!

  • Investments
Photo credits: pixabay.com

The trading week is coming to an end and on Thursday the German benchmark index DAX continues to trade below the psychological mark of 16,000 points at a level of 15,785 points and an increase of 0.10%. The rest of today and Friday remain to make a jump. It will probably depend on the guidance from the U.S., but at the hour, U.S. futures are all green. MDAX last traded at 34,135 points (+0.07%), TecDAX at 3,544 points (+0.07%) and SDAX at 15,626 points up 0.33%. Companies from the biotech sector are again in the focus of the investors today.

time to read: 1 minutes | Author: Mario Hose
ISIN: CARDIOL THERAPEUTICS | CA14161Y2006 , NOVAVAX INC. DL-_01 | US6700024010 , VALNEVA SE EO -_15 | FR0004056851

Table of contents:

    Author

    Mario Hose

    Mario Hose

    Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

    About the author

    Tag cloud

    Shares cloud

    Share price fireworks after announcement

    The share of Valneva can show the most trades on Tradegate so far on today's trading day. More than 5,600 executed orders have been counted so far. After yesterday's company announcement on the development of a Covid-19 vaccine, the share price increased from below 14.00 EUR to over 20.00 EUR. Currently, the share is trading at EUR 16.86, far from its daily high of EUR 21.20. Compared to the previous day's closing price, the shares are trading around 21% lower. The Novavax shares have also lost ground in recent weeks. In December 2021, the shares still changed hands at over EUR 200.00. Most recently, the shares were traded at EUR 84.20, 3.47% higher than the previous day.

    Investors are betting on the next Covid-19 phase

    Long-Covid is moving more and more into the focus of investors. Canadian biotech Cardiol Therapeutics successfully completed a USD 50 million capital increase in November 2021, significantly expanding its financial resources for product development. The company focuses on heart disease therapy. The proliferation of Covid-19 has significantly increased the need. The analysts of Canaccord and Cantor Fitzgerald grant the shares a price potential of CAD 10.00 and GBC Research even considers CAD 17.49 possible. At present with EUR 1.78 (approx. CAD 2.52) the shares change their owners. On the previous day, there was profit-taking in the shares after several days of price increases. But according to an old stock market saying, "Buy on dips!" - in other words, buy on weakness.

    On Feb. 17, 2022, Cardiol will present at the 'International Investment Forum - IIF' and provide insights to investors. (Free registration: ii-forum.com). Yesterday, a report on Cardiol by stock market expert Carsten Mainitz was also published on researchanalyst.com.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") currently hold or hold shares or other financial instruments of the aforementioned companies and speculate on their price developments. In this respect, they intend to sell or acquire shares or other financial instruments of the companies (hereinafter each referred to as a "Transaction"). Transactions may thereby influence the respective price of the shares or other financial instruments of the Company.
    In this respect, there is a concrete conflict of interest in the reporting on the companies.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
    For this reason, there is also a concrete conflict of interest.
    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Mario Hose

    Mario Hose

    Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

    About the author

    Related comments:

    Commented by Nico Popp on April 7th, 2026 | 07:25 CEST

    Congo in Focus: Barrick and Ivanhoe Pave the Way for DRC Gold

    • Mining
    • Gold
    • Commodities
    • geopolitics
    • Investments

    The global mining industry is at a turning point—demand for new deposits is rising, while globalization is increasingly reaching its limits, making diversified and redundant supply chains essential. In this market environment, the Democratic Republic of the Congo (DRC) has moved beyond its traditional role as a mere raw material supplier and is undergoing a significant transformation. The progress being made in the country is exemplified by the successes of companies like Barrick Mining and Ivanhoe Mines. Their multi-billion-dollar investments demonstrate that large-scale operations are indeed feasible in the DRC. The country's geological potential has once again drawn attention due to the recent record production at Barrick Mining's Kibali mine. While major corporations are successfully advancing projects in the DRC, junior explorers are also increasingly attracting investor attention. DRC Gold is capitalizing on this momentum and identifying new resources through drilling programs in close proximity to existing projects. Against the backdrop of declining reserves among major producers such as Barrick and Ivanhoe, the smaller company, led by German CEO Klaus Eckhof, offers an exciting opportunity to benefit from the new growth in the Congo.

    Read

    Commented by Tarik Dede on April 2nd, 2026 | 08:00 CEST

    Back to the Debasement Trade: Gold Stocks Like Kinross Gold, Lahontan Gold, and Newmont Poised to Benefit

    • Mining
    • Gold
    • Commodities
    • Investments

    Over the past year, the debasement trade has come into focus for many investors. The idea behind it is an investment strategy designed to protect one's assets from the creeping devaluation of currencies like the US dollar or the euro. As global debt continues to rise and central banks in countries like the US or Japan are massively buying up their own government debt, their currencies are being weakened. Creeping inflation, which is likely to be exacerbated by the war in the Persian Gulf, will then effectively result in taxpayers being expropriated. Economists have long realized that these countries will never repay their debts but will instead resort to massive inflation. This is what emperors and kings did in earlier times, and this is what heads of state and prime ministers will do today. Investors can protect themselves from these developments by investing in the gold sector while simultaneously generating returns.

    Read

    Commented by Armin Schulz on April 1st, 2026 | 07:35 CEST

    A Historic Opportunity in the Gold Market: Add Newmont, DRC Gold, and Agnico Eagle to Your Portfolio

    • Mining
    • Gold
    • Commodities
    • geopolitics
    • Investments

    The ongoing military standoff with Iran is sending shockwaves through financial markets worldwide. Gold, the classic safe-haven asset, has taken a hit due to the recent strength of the USD and is now drawing the attention of all investors. Steadily rising oil prices, supply bottlenecks, and the prospect of expansionary monetary policy from the Federal Reserve should further fuel the rally in the long term. Those who fail to act now could potentially miss out on a historic opportunity. We take a look at three exciting gold companies: Newmont, DRC Gold, and Agnico Eagle.

    Read